Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for identifying oversold conditions, typically below 30 [1] Company Summaries - **Boston Scientific Corp (BSX)**: Upgraded from Perform to Outperform by Oppenheimer analyst Steven Lichtman, with a price target raised from $118 to $125. The stock has a 52-week low of $80.64 and an RSI value of 27.3. Recent price action shows a 0.3% decline, closing at $98.23 [7] - **aTyr Pharma Inc (ATYR)**: Announced that its Phase 3 EFZO-FIT study did not meet its primary endpoint, leading to an 80% stock decline over five days. The stock has a 52-week low of $0.97 and an RSI value of 22.6. Recent price action shows a 2.4% gain, closing at $1.05 [7] - **Reviva Pharmaceuticals Holdings Inc (RVPH)**: Announced a $9 million public offering, resulting in a 21% decline over the past month. The stock has a 52-week low of $0.30 and an RSI value of 24.5. Recent price action shows a 3.7% gain, closing at $0.42 [7]

Core Insights - The health care sector has identified oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for assessing stock performance, with an RSI below 30 indicating oversold conditions [1] Company Summaries - **Boston Scientific Corp (BSX)**: Upgraded from Perform to Outperform by Oppenheimer analyst Steven Lichtman, with a price target raised from $118 to $125. The stock has fallen approximately 5% in the past five days, with a 52-week low of $80.64. Current RSI is 27.3, and shares closed at $98.23 [7] - **aTyr Pharma Inc (ATYR)**: Announced that its Phase 3 EFZO-FIT study did not meet its primary endpoint, leading to a stock decline of around 80% over the past five days, with a 52-week low of $0.97. Current RSI is 22.6, and shares closed at $1.05 [7] - **Reviva Pharmaceuticals Holdings Inc (RVPH)**: Recently priced a $9 million public offering, resulting in a stock decline of approximately 21% over the past month, with a 52-week low of $0.30. Current RSI is 24.5, and shares closed at $0.42 [7]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].

Industry Overview - Biotech and healthcare stocks are responding positively to clinical trial progress, regulatory developments, and economic indicators, particularly with the Federal Reserve's first rate cut of 2025, which is expected to improve funding conditions for capital-intensive sectors like biotechnology [1] Company Highlights - **Sonnet BioTherapeutics Holdings Inc. (SONN)**: Shares increased by 11.19% in after-hours trading, reaching $7.85 after a regular session close of $7.06. The stock has a 52-week range of $1.08 - $19.30. The company expanded clinical evaluation of its lead candidate, SON-1010, for ovarian cancer, reporting a strong safety profile and a partial response at the highest dose level [2][3] - **Akari Therapeutics Plc (AKTX)**: Shares surged 11.58% in after-hours trading to $0.8855 after closing at $0.7936. The stock has a 52-week range of $0.5710 - $3.8500. The increase follows a provisional patent filing for its antibody-drug conjugate platform aimed at cancer treatment, which is expected to enhance its intellectual property and support the development of first-in-class ADCs [4][5] - **Safety Shot Inc. (SHOT)**: Shares rose 9.75% in after-hours trading to $0.3333 after closing at $0.3037. The company announced a strategic refresh of its Board of Directors with three new members to strengthen its capabilities in digital assets and operations [6][7] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares climbed 10.09% in after-hours trading to $0.4451 after closing at $0.4043. The stock has a 52-week range of $0.3000 - $4.2800. The price movement follows a revised analyst rating maintaining a "Speculative Buy" while lowering the price target from $14.00 to $7.00. Reviva's lead candidate, brilaroxazine, is being developed for multiple neuropsychiatric and respiratory indications [8][9][10] - **Cognition Therapeutics Inc. (CGTX)**: Shares rose 7.48% in after-hours trading to $1.58 after closing down at $1.47. The company is focused on its lead candidate, Zervimesine, for Alzheimer's disease, and recently closed a $30 million offering to support its Phase 3 development [12][13]

[Report Overview](index=1&type=section&id=Report%20Overview) Reviva Pharmaceuticals provides an executive summary of its Q2 2025 financial results and strategic advancements, particularly for brilaroxazine in schizophrenia [Second Quarter 2025 Financial Results and Business Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results%20and%20Business%20Highlights) Reviva Pharmaceuticals reported its Q2 2025 financial results and key business highlights, primarily focusing on the advancement of its lead drug candidate, brilaroxazine, for schizophrenia. A significant milestone was the successful completion of the OLE 1-year trial, reinforcing its safety and efficacy profile, with a planned FDA meeting in Q4 2025 and a target NDA submission in Q2 2026 - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage pharmaceutical company developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases[1](index=1&type=chunk) - Planned meeting with the Food and Drug Administration (FDA) to discuss brilaroxazine's path to approval for schizophrenia in **Q4 2025**; potential NDA submission targeted for **Q2 2026**[1](index=1&type=chunk) [Clinical Program and Business Highlights](index=1&type=section&id=Clinical%20Program%20and%20Business%20Highlights) This section details the clinical progress of brilaroxazine, including successful trial completion, and outlines the company's patent strategy and pipeline expansion efforts [Brilaroxazine Clinical Development](index=1&type=section&id=Brilaroxazine%20Clinical%20Development) Reviva achieved major clinical milestones for brilaroxazine, including the successful completion of its global OLE 1-year trial, demonstrating sustained broad-spectrum efficacy and a well-tolerated safety profile. The company is preparing for an End-of-Phase 3 meeting with the FDA in Q4 2025 to discuss NDA submission - Successful completion of the global OLE 1-year trial for brilaroxazine, reinforcing long-term safety, broad-spectrum sustained efficacy, and strong adherence profile[2](index=2&type=chunk) - Once daily brilaroxazine (pooled 15, 30, and 50 mg, N=446) demonstrated robust broad-spectrum efficacy sustained over 1-year, with PANSS total score reduction of **–18.1**, positive symptoms **–5.0**, negative symptoms **–4.4**, and negative Marder factor **–4.4**[5](index=5&type=chunk) - Brilaroxazine was generally well tolerated with a discontinuation rate of **35%** after 1-year for pooled doses[5](index=5&type=chunk) [Patent Portfolio and Pipeline Expansion](index=1&type=section&id=Patent%20Portfolio%20and%20Pipeline%20Expansion) Reviva is actively expanding its diversified patent portfolio for brilaroxazine, aiming for market exclusivity up to 2045 and beyond, covering composition of matter and lifecycle management strategies for various indications - Continuing efforts aimed at expansion of strong diversified patent portfolio comprising composition of matter and lifecycle management strategies for innovative formulations and method of treatment for different major indications with clear regulatory path including potential patent and/or market exclusivity up to **2045** and beyond[5](index=5&type=chunk) [Anticipated Milestones and Events](index=2&type=section&id=Anticipated%20Milestones%20and%20Events) Reviva Pharmaceuticals outlines key upcoming corporate and clinical milestones, including regulatory meetings, NDA submissions, and financial activities [Key Milestones and Corporate Activities](index=2&type=section&id=Key%20Milestones%20and%20Corporate%20Activities) Reviva has outlined several key upcoming milestones, including an FDA meeting in Q4 2025, a target NDA submission for brilaroxazine in schizophrenia in Q2 2026, and an IND submission for a new brilaroxazine formulation in psoriasis by Q2 2026. The company also completed a $10.0 million public equity offering and is assessing plans for a potential Phase 3 RECOVER-2 trial - Planned meeting with FDA to discuss brilaroxazine's path to approval in **Q4 2025**[9](index=9&type=chunk) - Potential NDA submission for brilaroxazine in schizophrenia targeted in **Q2 2026**[9](index=9&type=chunk) - Investigational new drug application (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by **Q2 2026**[9](index=9&type=chunk) - Completed public equity offering raising gross proceeds of **$10.0 million**, before deducting placement agent fees and other offering expenses[9](index=9&type=chunk) - Plans are being assessed to initiate a potential registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia pending FDA recommendation for a path to approval[9](index=9&type=chunk) - Pursuing partnership opportunities for the development of our pipeline[9](index=9&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Results%20for%20June%2030%2C%202025) This section presents Reviva's Q2 2025 financial results, including condensed balance sheets and statements of operations, highlighting key financial metrics and changes [Q2 2025 Financial Summary](index=2&type=section&id=Q2%202025%20Financial%20Summary) For the three months ended June 30, 2025, Reviva reported a reduced net loss of $6.1 million, an improvement from $7.9 million in the prior year period. Cash and cash equivalents stood at $10.4 million as of June 30, 2025, down from $13.5 million at December 31, 2024 Net Loss and Net Loss per Share | Metric | Q2 2025 | Q2 2024 | Change (YoY) | | :----- | :------ | :------ | :----------- | | Net Loss | $(6.1) million | $(7.9) million | $(1.8) million (Improved) | | Net Loss per Share (Basic & Diluted) | $(0.12) | $(0.26) | $(0.14) (Improved) | Cash and Cash Equivalents | Metric | June 30, 2025 | December 31, 2024 | Change | | :----- | :------------ | :---------------- | :----- | | Cash and Cash Equivalents | $10.4 million | $13.5 million | $(3.1) million | [Condensed Consolidated Balance Sheets (Unaudited)](index=4&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS%20(UNAUDITED)) As of June 30, 2025, Reviva's total assets were $11.6 million, a decrease from $15.5 million at December 31, 2024. This was primarily due to a reduction in cash and cash equivalents, prepaid clinical trial costs, and other current assets. Total liabilities also decreased, while stockholders' equity moved into a deficit position Condensed Consolidated Balance Sheets (Unaudited) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :----------------- | :------------ | :---------------- | | Cash and cash equivalents | $10,363,714 | $13,476,331 | | Total current assets | $10,815,125 | $14,683,367 | | Total Assets | $11,634,846 | $15,503,088 | | Total current liabilities | $12,077,303 | $14,601,506 | | Total Liabilities | $12,093,993 | $14,690,516 | | Total stockholders' equity (deficit) | $(459,147) | $812,572 | [Condensed Consolidated Statements of Operations (Unaudited)](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20(UNAUDITED)) For the three months ended June 30, 2025, total operating expenses decreased to $6.1 million from $8.1 million in the prior year, primarily due to a significant reduction in research and development expenses. This led to a lower net loss of $6.1 million compared to $7.9 million in Q2 2024 Condensed Consolidated Statements of Operations (Unaudited) | Operating Expense | Three Months Ended June 30, 2025 ($) | Three Months Ended June 30, 2024 ($) | Six Months Ended June 30, 2025 ($) | Six Months Ended June 30, 2024 ($) | | :---------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $3,724,755 | $5,584,347 | $7,838,292 | $11,368,212 | | General and administrative | $2,348,227 | $2,545,296 | $4,772,857 | $4,683,537 | | Total operating expenses | $6,072,982 | $8,129,643 | $12,611,149 | $16,051,749 | | Net loss | $(6,053,610) | $(7,859,919) | $(12,486,450) | $(15,293,527) | | Net loss per share (Basic and diluted) | $(0.12) | $(0.26) | $(0.25) | $(0.51) | [About Reviva Pharmaceuticals Holdings, Inc.](index=2&type=section&id=About%20Reviva) Reviva Pharmaceuticals is a late-stage biopharmaceutical company focused on CNS, inflammatory, and cardiometabolic diseases, with a pipeline featuring brilaroxazine and RP1208 [Company Overview and Pipeline](index=2&type=section&id=Company%20Overview%20and%20Pipeline) Reviva is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases. Its pipeline includes brilaroxazine (RP5063) and RP1208, both proprietary new chemical entities with granted composition of matter patents - Reviva is a late-stage biopharmaceutical company developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases[7](index=7&type=chunk) - Current pipeline includes two drug candidates, **brilaroxazine (RP5063)** and **RP1208**, both new chemical entities discovered in-house with composition of matter patents granted in the US, Europe, and other countries[7](index=7&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section provides a disclaimer regarding forward-looking statements, outlining inherent risks and uncertainties, and clarifies the company's non-obligation to update future projections [Disclaimer and Risk Factors](index=2&type=section&id=Disclaimer%20and%20Risk%20Factors) This section contains standard forward-looking statements regarding the company's plans for its brilaroxazine program, potential approvals, FDA meetings, NDA submissions, clinical trial plans, market opportunities, and financial performance. These statements are based on current expectations and involve known and unknown risks and uncertainties, cautioning investors against undue reliance. The company explicitly states it undertakes no obligation to publicly update these statements - Forward-looking statements relate to future events or financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results to differ materially[10](index=10&type=chunk) - The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise[10](index=10&type=chunk) [Contacts](index=3&type=section&id=Corporate%20Contact) This section provides essential contact information for corporate and investor relations inquiries for Reviva Pharmaceuticals Holdings, Inc [Corporate and Investor Relations Information](index=3&type=section&id=Corporate%20and%20Investor%20Relations%20Information) Contact information for corporate inquiries and investor relations is provided for Reviva Pharmaceuticals Holdings, Inc - Corporate Contact: **Laxminarayan Bhat, PhD**, Reviva Pharmaceuticals Holdings, Inc. (www.revivapharma.com)[11](index=11&type=chunk) - Investor Relations Contact: **PJ Kelleher**, LifeSci Advisors, LLC (pkelleher@lifesciadvisors.com)[11](index=11&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the quarterly period ended June 30, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 For the transition period from ____ to ____ Commission file number: 001-38634 Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4306526 ...

Core Insights - Reviva Pharmaceuticals is advancing its brilaroxazine program towards potential registration, with a planned meeting with the FDA in Q4 2025 to discuss the New Drug Application (NDA) submission targeted for Q2 2026 [2][5] Clinical Program and Business Highlights - The company successfully completed a 1-year open-label extension (OLE) trial for brilaroxazine, demonstrating a well-tolerated safety profile and robust broad-spectrum efficacy across all symptom domains in schizophrenia [1][5] - Brilaroxazine showed a significant reduction in PANSS total score by 18.1, positive symptoms by 5.0, and negative symptoms by 4.4, with a discontinuation rate of 35% after 1 year [5] - Reviva is expanding its patent portfolio, aiming for potential patent and market exclusivity up to 2045 and beyond [5] - A late-breaking poster presentation on the RECOVER 12-month OLE trial was presented at the 2025 ASCP annual meeting [5] Financial Results - For the second quarter ended June 30, 2025, the company reported a net loss of approximately $6.1 million, or $0.12 per share, compared to a net loss of approximately $7.9 million, or $0.26 per share, for the same period in 2024 [10][13] - As of June 30, 2025, cash and cash equivalents totaled approximately $10.4 million, down from approximately $13.5 million as of December 31, 2024 [10][11] Anticipated Milestones and Events - The company plans to initiate a potential registrational Phase 3 RECOVER-2 trial for brilaroxazine pending FDA recommendations [5] - An IND submission for a liposomal-gel formulation of brilaroxazine in psoriasis is expected by Q2 2026 [10]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 20 million shares of common stock and associated warrants, aiming to raise approximately $10 million to fund research and development activities and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and Series C and D warrants, priced at $0.50 per share, with total gross proceeds expected to be around $10 million before expenses [1]. - Series C Warrants and Series D Warrants will have an exercise price of $0.50 per share, with Series C Warrants expiring in five years and Series D Warrants expiring in 12 months [2]. - The closing of the offering is anticipated on or about June 27, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [6]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and protected by composition of matter patents in multiple regions [6].

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. plans to offer shares of its common stock and warrants in a public offering to fund research and development activities and for general corporate purposes [1][2]. Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [5]. - The company's pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house and have been granted composition of matter patents in multiple regions [5]. Offering Details - The offering will be conducted under an effective shelf registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission (SEC) [3]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2].

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a presentation scheduled at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference [1][2]. Company Overview - Reviva is engaged in discovering, developing, and commercializing next-generation therapeutics targeting diseases that pose significant burdens to society and patients [2]. - The company's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [2]. - Reviva has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [2]. Conference Details - The H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference will feature a pre-recorded presentation by Reviva's CEO, Laxminarayan Bhat, available on-demand starting June 16, 2025 [2]. - The conference is virtual and registration is required for access [2].